Recently, the predictive signature for the responsiveness of malignant melanoma cells to the combination of Birinapant and the latest generation hexavalent TRAIL-based biologic IZI1551 was generated (Vetma et al., 2020). This evidence concerns the gene TNFSF10 and melanoma.